WO2009047443A2 - Cosmetic composition for improving skin condition - Google Patents

Cosmetic composition for improving skin condition Download PDF

Info

Publication number
WO2009047443A2
WO2009047443A2 PCT/FR2008/051663 FR2008051663W WO2009047443A2 WO 2009047443 A2 WO2009047443 A2 WO 2009047443A2 FR 2008051663 W FR2008051663 W FR 2008051663W WO 2009047443 A2 WO2009047443 A2 WO 2009047443A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
weight
advantageously
aqueous
skin
Prior art date
Application number
PCT/FR2008/051663
Other languages
French (fr)
Other versions
WO2009047443A3 (en
Inventor
Jean-Noël THOREL
Original Assignee
Thorel Jean-Noel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thorel Jean-Noel filed Critical Thorel Jean-Noel
Publication of WO2009047443A2 publication Critical patent/WO2009047443A2/en
Publication of WO2009047443A3 publication Critical patent/WO2009047443A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9711Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • A61K8/9722Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88Two- or multipart kits
    • A61K2800/884Sequential application

Definitions

  • the notion of "improvement of the state of the skin” refers in particular to the improvement of: - its brightness by virtue of its state of hydration, its firmness through the quality of its tissues. support, its appeasement through the stress it undergoes, its transparency through the fineness of its grain.
  • the Applicant has developed a new topical cosmetic composition comprising: an aqueous extract of an alga called Blidingia Minima, an aqueous extract of an alga called Laminaria Saccharina, an oily extract of an alga called Laminaria Ochroleuca, - optionally, an aqueous extract of plankton.
  • the topical cosmetic composition of the invention contains (in percentage by weight): from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an aqueous extract of
  • the composition of the invention also contains at least one component capable of acting directly on the visible dysfunctions of the skin, such as, as already mentioned, hydration, hyperseborrhoea, structural alteration, cellular stress, without breaking the cell balance.
  • the composition also contains at least one, advantageously, the following four constituents respectively: an aqueous soy extract inducing the synthesis of aquaporins and thereby ensuring better circulation of the water in the skin and nutrients in the cell, an alcoholic extract of mushroom rich in agaric acid, such as for example an extract of Polyporus Officinalis, extract having an astringent action for tightening the pores of the skin and thus to limit the secretion of sebum at cutaneous surface level as well as the microbial proliferation inside the pilosebaceous canal, a peptide, such as, for example, a tetrapeptide, optionally acetylated capable of stimulating collagen synthesis with a view to improving the quality of the support tissues of the skin, advantageously acetyl tetrapeptide-9:
  • composition may contain any excipient of suitable formulation to make it usable in the form of a particular serum and in particular water and fats such as for example glycerin, silicones and derivatives.
  • the composition contains: from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an aqueous extract of
  • Laminaria Saccharina 0.2 to 5%, preferably 0.5 to 2% by weight of an oily extract of
  • Laminaria Ochroleuca from 0.05 to 5%, preferably from 0.05 to 2% by weight of an aqueous plankton extract. between 0.0005 and 1%, advantageously between 0.005 and 0.1% of an aqueous soy extract, between 0.05 and 2%, advantageously between 0.1 and 1% of an alcoholic mushroom extract, advantageously an extract of Polyporus Officinalis, between 1 and 10%, advantageously between 2 and 5% of an acetylated tetrapeptide, for example acetyl tetrapeptide-9: N-acetyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, between 0.0005 and 1%, advantageously between 0.005 and 0.1% rhamnose, between 65 and 85% by weight of water, between 5 and 20% by weight of fat.
  • Figure 7 is a graphical representation of the effect of the cell concentrate on the soothing of the skin.
  • the energies needed and delivered by the cell cycle can be "lighted" by Kirlian photography or dynamic electro-dynamic photography.
  • Aim to evaluate the biomechanical properties of the skin, especially the firmness, after 1 month use of the Cellular Concentrate, under normal conditions. Topics: 18 volunteers.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a topic cosmetic composition that comprises: an aqueous extract of an alga named Blidingia Minima, an aqueous extract of an alga named Laminaria Saccharina, and an oily extract of an alga named Laminaria Ochroleuca.

Description

COMPOSITION COSMETIQUE DESTINEE A AMELIORER L'ETAT DE LA PEAU COSMETIC COMPOSITION FOR IMPROVING THE CONDITION OF THE SKIN
L'invention a pour objet une nouvelle composition cométique contenant un mélange de constituants destinés à améliorer l'état de la peau en agissant sur un certain nombre de dysfonctionnements.The subject of the invention is a novel cometic composition containing a mixture of constituents intended to improve the state of the skin by acting on a certain number of dysfunctions.
Dans la présente invention la notion « d'amélioration de l'état de la peau » désigne notamment l'amélioration de : - son éclat par le biais de son état d'hydratation, sa fermeté par le biais de la qualité de ses tissus de soutien, son apaisement par le biais du stress qu'elle subit, sa transparence par le biais de la finesse de son grain.In the present invention, the notion of "improvement of the state of the skin" refers in particular to the improvement of: - its brightness by virtue of its state of hydration, its firmness through the quality of its tissues. support, its appeasement through the stress it undergoes, its transparency through the fineness of its grain.
L'ensemble de ces dysfonctionnements est en général corrigé au cas par cas au moyen de compositions cosmétiques qui présentent l'inconvénient de créer un déséquilibre du métabolisme des cellules présentes dans l'épiderme. Ces cellules fonctionnent selon un cycle comportant essentiellement 4 phases distinctes que sont : la nutrition correspondant aux besoins en eau, sels minéraux, vitamines etc .de la cellule, la construction correspondant à la synthèse des protéines, la détoxification correspondant à l'élimination des déchets produits par la cellule, la régénération correspondant à la multiplication des cellules.All of these dysfunctions are generally corrected case by case by means of cosmetic compositions which have the disadvantage of creating an imbalance of the metabolism of the cells present in the epidermis. These cells operate in a cycle comprising essentially 4 distinct phases that are: nutrition corresponding to the water, mineral salts, vitamins etc. of the cell, the construction corresponding to the synthesis of proteins, the detoxification corresponding to the elimination of waste produced by the cell, the regeneration corresponding to the multiplication of the cells.
Or, il apparaît que la rupture de cet équilibre au niveau de l'une ou de l'autre de ces phases entraîne un dysfonctionnement visible au niveau de la peau. Il s'agit d'un état déshydraté en cas de manque de nutriments, d'une hyperséborrhée en cas de détoxification affaiblie, d'une altération des structures en cas de construction défaillante et d'un stress cellulaire entraînant une hyper réactivité cellulaire en cas d'absence de régénération.However, it appears that the rupture of this equilibrium at one or the other of these phases causes a visible dysfunction in the skin. It is a dehydrated state in the event of lack of nutrients, hyperseborrhoea in the event of weakened detoxification, structural alteration in case of faulty construction and cellular stress leading to cellular hyper reactivity in case lack of regeneration.
L'équilibre du cycle cellulaire peut être mis en évidence par la technique dite deThe balance of the cell cycle can be demonstrated by the technique known as
« photographie kirlian ». Cette photographie montre la répartition de l'énergie dans la cellule via des zones de lumière désignées « strimers » réparties autour d'un cercle."Kirlian photography". This photograph shows the distribution of energy in the cell via light zones called "strimers" distributed around a circle.
Une répartition homogène et une intensité élevée des strimers sont le signe d'un équilibre cellulaire satisfaisant. La figure 1 représente dans ce sens le cercle Kirlian d'une cellule jeune. Au contraire, une répartition aléatoire et une intensité limitée des strimers sont le signe d'un déséquilibre du cycle cellulaire. La figure 2 représente dans ce sens le cercle Kirlian d'une cellule âgée.A homogeneous distribution and a high intensity of the strimers are the sign of a satisfactory cell balance. Figure 1 represents in this sense the Kirlian circle of a young cell. On the contrary, a random distribution and a limited intensity of the strimers are the sign of an imbalance of the cell cycle. Figure 2 represents in this sense the Kirlian circle of an aged cell.
Plutôt que d'agir directement et exclusivement sur les dysfonctionnements visibles de la peau, ce que font aujourd'hui la plupart des compositions cosmétiques, le Demandeur a cherché à rétablir au préalable l'équilibre cellulaire de l'épiderme. Plus précisément, l'objectif de l'invention a été de développer une composition rétablissant l'équilibre cellulaire en agissant directement sur le cycle cellulaire de manière à rendre les cellules réceptives aux effets de composants appliqués ultérieurement ou simultanément et destinés pour leur part, à lutter directement contre les dysfonctionnements visibles de la peau.Rather than acting directly and exclusively on the visible dysfunction of the skin, which is what most cosmetic compositions do today, the Applicant sought to restore the cellular equilibrium of the epidermis beforehand. More specifically, the object of the invention has been to develop a composition that restores the cell balance by acting directly on the cell cycle so as to render the cells receptive to the effects of components applied subsequently or simultaneously and intended for their part, to fight directly against visible dysfunctions of the skin.
Pour ce faire, le Demandeur a mis au point une nouvelle composition cosmétique topique comprenant : un extrait aqueux d'une algue dénommée Blidingia Minima, un extrait aqueux d'une algue dénommée Laminaria Saccharina, un extrait huileux d'une algue dénommée Laminaria Ochroleuca, - éventuellement, un extrait aqueux de plancton.To do this, the Applicant has developed a new topical cosmetic composition comprising: an aqueous extract of an alga called Blidingia Minima, an aqueous extract of an alga called Laminaria Saccharina, an oily extract of an alga called Laminaria Ochroleuca, - optionally, an aqueous extract of plankton.
Dans un mode de réalisation avantageux, la composition contient les quatre extraits ci- avant identifiés.In an advantageous embodiment, the composition contains the four extracts identified above.
Le Demandeur a démontré qu'une telle composition permettait de rétablir l'équilibre du cycle cellulaireThe Applicant has demonstrated that such a composition can restore the balance of the cell cycle
Bien entendu l'ensemble de ces extraits sont obtenus dans des conditions bien connues de l'homme du métier, avantageusement à partir d'algues fraîches par extraction en milieu aqueux, éventuellement en présence d'alcool. Les conditions d'extraction ne nécessitent donc pas d'être d'avantage décrites dans le détail.Of course all of these extracts are obtained under conditions well known to those skilled in the art, preferably from fresh algae by extraction in aqueous medium, optionally in the presence of alcohol. The extraction conditions do not therefore need to be described in detail.
En pratique, la composition cosmétique topique de l'invention contient (en pourcentage en poids) : - de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux deIn practice, the topical cosmetic composition of the invention contains (in percentage by weight): from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an aqueous extract of
Blidingia Minima, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux de Laminaria Saccharina, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait huileux de Laminaria Ochroleuca, - de 0.05 à 5%, de préférence de 0.05 à 2% en poids d'un extrait aqueux de plancton.Blidingia Minima, from 0.2 to 5%, preferably from 0.5 to 2% by weight of an aqueous extract of Laminaria Saccharina, from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an oily extract of Laminaria Ochroleuca, 0.05 to 5%, preferably 0.05 to 2% by weight of an aqueous plankton extract.
Dans un mode de réalisation avantageux, la composition de l'invention contient en outre au moins un composant capable d'agir directement sur les dysfonctionnements visibles de la peau, tels que comme déjà mentionné, hydratation, hyperséborrhée, altération des structures, stress cellulaire, sans pour autant rompre l'équilibre cellulaire.In an advantageous embodiment, the composition of the invention also contains at least one component capable of acting directly on the visible dysfunctions of the skin, such as, as already mentioned, hydration, hyperseborrhoea, structural alteration, cellular stress, without breaking the cell balance.
En d'autres termes, la composition contient en outre au moins un, avantageusement les quatre constituants suivants respectivement : - un extrait aqueux de soja induisant la synthèse d'aquaporines et assurant par la même, une meilleure circulation de l'eau dans la peau et des éléments nutritifs dans la cellule, un extrait alcoolique de champignon riche en acide agarique, tel que par exemple un extrait de Polyporus Officinalis, extrait présentant une action astringente permettant de resserrer les pores de la peau et ainsi de limiter la sécrétion de sébum au niveau de la surface cutanée ainsi que la prolifération microbienne à l'intérieur du canal pilosébacé, un peptide, tel que par exemple un tétrapeptide, éventuellement acétylé apte à stimuler la synthèse de collagène en vue de l'amélioration de la qualité des tissus de soutien de la peau, avantageusement le Acétyl Tétrapeptide- 9 :In other words, the composition also contains at least one, advantageously, the following four constituents respectively: an aqueous soy extract inducing the synthesis of aquaporins and thereby ensuring better circulation of the water in the skin and nutrients in the cell, an alcoholic extract of mushroom rich in agaric acid, such as for example an extract of Polyporus Officinalis, extract having an astringent action for tightening the pores of the skin and thus to limit the secretion of sebum at cutaneous surface level as well as the microbial proliferation inside the pilosebaceous canal, a peptide, such as, for example, a tetrapeptide, optionally acetylated capable of stimulating collagen synthesis with a view to improving the quality of the support tissues of the skin, advantageously acetyl tetrapeptide-9:
N-Acétyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, un saccharide, tel que par exemple le rhamnose permettant de limiter les phénomènes d'inflammation.N-Acetyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, a saccharide, such as for example rhamnose to limit the phenomena of inflammation.
Dans un mode de réalisation avantageux, la composition contient en outre, en poids de la composition totale : entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% d'un extrait aqueux de soja, entre 0.05 et 2%, avantageusement entre 0.1 et 1% d'un extrait alcoolique de champignon, avantageusement un extrait de Polyporus Officinalis, entre 1 et 10%, avantageusement entre 2 et 5% d'un tétrapeptide acétylé par exemple Acétyl Tétrapeptide- 9 : N-Acétyl L-Glutaminyl L-Aspartyl L-VaIyIIn an advantageous embodiment, the composition additionally contains, by weight of the total composition: between 0.0005 and 1%, advantageously between 0.005 and 0.1% of an aqueous soy extract, between 0.05 and 2%, advantageously between 0.1 and 1% of an alcoholic extract of mushroom, advantageously an extract of Polyporus Officinalis, between 1 and 10%, advantageously between 2 and 5% of an acetyl tetrapeptide, for example acetyl tetrapeptide-9: N-acetyl L-Glutaminyl L-Aspartyl L-VaIyI
L-Histidine, entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% de rhamnose.L-Histidine, between 0.0005 and 1%, advantageously between 0.005 and 0.1% of rhamnose.
Bien entendu, la composition de l'invention peut contenir d'autres ingrédients tels que notamment des agents anti-radicalaires (par exemple acide ascorbique et dérivés, SOD, acétate de tocophérol, flavonoides), agent anti-oxydant (BHT, etc.), agent séquestrants (EDTA..).Of course, the composition of the invention may contain other ingredients such as in particular anti-radical agents (for example ascorbic acid and derivatives, SOD, tocopherol acetate, flavonoids), anti-oxidizing agent (BHT, etc.). , sequestering agent (EDTA ..).
De même, la composition peut contenir tout excipient de formulation adéquat pour la rendre utilisable sous la forme d'un sérum notamment et en particulier de l'eau et des matières grasses telles que par exemple glycérine, silicones et dérivés.Similarly, the composition may contain any excipient of suitable formulation to make it usable in the form of a particular serum and in particular water and fats such as for example glycerin, silicones and derivatives.
Dans un mode de réalisation particulier, la composition contient : de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux deIn a particular embodiment, the composition contains: from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an aqueous extract of
Blidingia Minima, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux deBlidingia Minima, from 0.2 to 5%, preferably from 0.5 to 2% by weight of an aqueous extract of
Laminaria Saccharina, - de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait huileux deLaminaria Saccharina, 0.2 to 5%, preferably 0.5 to 2% by weight of an oily extract of
Laminaria Ochroleuca, de 0.05 à 5%, de préférence de 0.05 à 2% en poids d'un extrait aqueux de plancton. entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% d'un extrait aqueux de soja, entre 0.05 et 2%, avantageusement entre 0.1 et 1% d'un extrait alcoolique de champignon, avantageusement un extrait de Polyporus Officinalis, , entre 1 et 10%, avantageusement entre 2 et 5% d'un tétrapeptide acétylé par exemple Acétyl Tétrapeptide- 9 : N-Acétyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% de rhamnose, entre 65 et 85% en poids d'eau, entre 5 et 20% en poids de matière grasse.Laminaria Ochroleuca, from 0.05 to 5%, preferably from 0.05 to 2% by weight of an aqueous plankton extract. between 0.0005 and 1%, advantageously between 0.005 and 0.1% of an aqueous soy extract, between 0.05 and 2%, advantageously between 0.1 and 1% of an alcoholic mushroom extract, advantageously an extract of Polyporus Officinalis, between 1 and 10%, advantageously between 2 and 5% of an acetylated tetrapeptide, for example acetyl tetrapeptide-9: N-acetyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, between 0.0005 and 1%, advantageously between 0.005 and 0.1% rhamnose, between 65 and 85% by weight of water, between 5 and 20% by weight of fat.
Le Demandeur a par ailleurs démontré que la mise en œuvre de la composition de l'invention permettait d'optimiser l'action d'une composition cosmétique distincte appliquée ultérieurement. En d'autres termes et comme déjà dit, la composition de l'invention permet de rétablir l'équilibre du cycle cellulaire et de rendre la peau réceptive à l'action d'une composition ultérieure.The Applicant has furthermore demonstrated that the use of the composition of the invention makes it possible to optimize the action of a distinct cosmetic composition. applied later. In other words and as already said, the composition of the invention makes it possible to restore the equilibrium of the cell cycle and to make the skin receptive to the action of a subsequent composition.
Dès lors, la composition peut être mise en œuvre dans le cadre d'un protocole de soin. L'invention a donc également pour objet un procédé de traitement cosmétique de la peau en vue d'en améliorer l'état et consistant, dans un premier temps, à appliquer ladite composition sur la peau, puis dans un second temps, à appliquer une seconde composition destinée à corriger un dysfonctionnement visible de la peau tel que par exemple déshydratation ou encore hyper séborrhée.Therefore, the composition can be implemented as part of a care protocol. The subject of the invention is therefore also a process for the cosmetic treatment of the skin with a view to improving its state and consisting, in a first step, in applying said composition to the skin, then in a second step, in applying a second composition intended to correct a visible dysfunction of the skin such as for example dehydration or hyper seborrhea.
L'invention et les avantages qui en découlent ressortiront bien des exemples suivants à l'appui des figures annexées.The invention and the advantages thereof will emerge from the following examples in support of the appended figures.
La figure 1 est une photographie représentant le cercle Kirlian d'une cellule jeune.Figure 1 is a photograph showing the Kirlian circle of a young cell.
La figure 2 est une photographie représentant le cercle Kirlian d'une cellule âgée.Figure 2 is a photograph showing the Kirlian circle of an aged cell.
La figure 3 est une photographie représentant le cercle Kirlian d'une cellule âgée traitée par le concentré cellulaire.Figure 3 is a photograph showing the Kirlian circle of an aged cell treated with the cell concentrate.
La figure 4 est une représentation graphique de l'évaluation in vivo de la fermeté cutanée.Figure 4 is a graphical representation of the in vivo evaluation of cutaneous firmness.
Les figures 5 et 6 sont des photographies réalisées sur prises d'empreintes au niveau du visage avant traitement (figure 6) et après traitement (figure 5), par le concentré cellulaire.Figures 5 and 6 are photographs taken on fingerprints in the face before treatment (Figure 6) and after treatment (Figure 5), by the cell concentrate.
La figure 7 est une représentation graphique de l'effet du concentré cellulaire sur l'apaisement de la peau.Figure 7 is a graphical representation of the effect of the cell concentrate on the soothing of the skin.
La figure 8 est une représentation graphique de l'effet du concentré cellulaire sur un soin associé. Figure 8 is a graphical representation of the effect of cell concentrate on associated care.
I/ La composition testée « concentré cellulaire »I / The tested composition "cellular concentrate"
La composition testée dans les essais qui suivent désignée « concentré cellulaire » à la composition suivante en pourcentage en poids:The composition tested in the following tests designated "cell concentrate" to the following composition in percentage by weight:
Figure imgf000007_0001
Figure imgf000007_0001
II/ Photo kirlian d'une cellule âgée traitée par le concentré cellulaireII / Kirlian photo of an elderly cell treated with cell concentrate
Les énergies nécessaires et dispensées par le cycle cellulaire peuvent être mises en « lumière » par la photo Kirlian ou photographie de type électro graphie dynamique.The energies needed and delivered by the cell cycle can be "lighted" by Kirlian photography or dynamic electro-dynamic photography.
Cette photo met en évidence d'une part la valeur énergétique du concentré cellulaire et d'autre part, renseigne sur les zones d'activités du concentré cellulaire dans la cellule.This photo highlights on the one hand the energy value of the cell concentrate and on the other hand, provides information on the activity zones of the cell concentrate in the cell.
On peut ainsi visualiser, via les « strimers » de la photo Kirlain, le degré d'apport et d'utilisation de l'énergie par la cellule. Si équilibre il y a dans la cellule, il sera symbolisé par un « cercle Kirlian » homogène, aux strimers intenses et relativement fournis. Ce sera également le symbole d'un cycle cellulaire en fonctionnement optimal et d'une vibration équilibrée avec l'environnement.It is thus possible to visualize, via the "strimers" of the Kirlain photo, the degree of contribution and use of the energy by the cell. If there is equilibrium in the cell, it will be symbolized by a homogeneous "Kirlian circle", with intense and relatively furnished strimers. It will also be the symbol of an optimal functioning cell cycle and a balanced vibration with the environment.
Les figures 1, 2 et 3 sont des photos du cercle kirlian d'une cellule jeune (figure 1), cellule âgée (figure 2) et cellule âgée traitée avec le concentré cellulaire (figure 3). Comme le montre cette dernière, le concentré cellulaire permet de rétablir l'équilibre du cycle cellulaire avec une zone d'activité homogène. HI/ Efficacité de la composition de l'invention sur l'amélioration de l'état de la peauFigures 1, 2 and 3 are pictures of the kirlian circle of a young cell (Figure 1), aged cell (Figure 2) and aged cell treated with the cell concentrate (Figure 3). As shown by the latter, the cell concentrate makes it possible to restore the equilibrium of the cell cycle with a zone of homogeneous activity. HI / Effectiveness of the composition of the invention on improving the state of the skin
1/ Eclat de la peau : pouvoir hydratant1 / Eclat of the skin: moisturizing power
But : évaluer et comparer l'état d'hydratation naturel de la peau avant et après utilisation du Concentré Cellulaire en application biquotidienne pendant 28 jours.Purpose: To evaluate and compare the natural state of hydration of the skin before and after using the Cellular Concentrate twice daily for 28 days.
Sujets : 18 volontaires.Topics: 18 volunteers.
Protocole : mesures réalisées à l'aide d'un cornéomètre, au minimum 15mn après nettoyage de la peau, rinçage à l'eau et séchage.Protocol: measurements using a corneometer, at least 15 minutes after cleaning the skin, rinsing with water and drying.
Résultats :Results:
Le Concentré Cellulaire permet d'augmenter le taux d'hydratation cutané naturel de quasiment 15% par rapport au taux basai et ceci après une utilisation bi quotidienne pendant 1 mois.The Cellular Concentrate makes it possible to increase the rate of natural skin hydration by almost 15% compared to the basal rate and this after a bi daily use for 1 month.
2/ Fermeté de la peau in vivo2 / Firmness of the skin in vivo
But : évaluer les propriétés biomécaniques de la peau, notamment la fermeté, après utilisation pendant 1 mois du Concentré Cellulaire, en conditions normales. Sujets : 18 volontaires.Aim: to evaluate the biomechanical properties of the skin, especially the firmness, after 1 month use of the Cellular Concentrate, under normal conditions. Topics: 18 volunteers.
Protocole : mesure des propriétés bio mécaniques à l'aide du cuto mètre qui va évaluer le relâchement de la peau (plus le relâchement diminue, plus la peau est tendue et ferme).Protocol: measurement of the bio mechanical properties using the cutometer which will evaluate the relaxation of the skin (the more the relaxation decreases, the more the skin is taut and firm).
Résultats : Le produit Concentré Cellulaire permet une amélioration significative de la fermeté de la peau (+13%) après utilisation bi quotidienne pendant 1 mois (figure 4).Results: The Cellular Concentrate product provides a significant improvement in the firmness of the skin (+ 13%) after daily use for 1 month (Figure 4).
3/ Transparence de la peau3 / Transparency of the skin
But : évaluer et comparer le grain de la peau avant et après utilisation du ConcentréPurpose: to evaluate and compare skin texture before and after using Concentrate
Cellulaire en application biquotidienne pendant 28 jours.Cellular application twice daily for 28 days.
Sujets : 18 volontaires.Topics: 18 volunteers.
Protocole : photos réalisées sur prises d'empreintes au niveau du visage.Protocol: photos taken on fingerprints on the face.
Résultats : comme le montre la figure 6, le grain de la peau est significativement affiné par rapport à la peau non traitée (figure 5). La peau est plus fine, plus nette, plus éclatante, plus transparente. 4/ Apaisement de la peauResults: As shown in Figure 6, the grain of the skin is significantly refined compared to the untreated skin (Figure 5). The skin is thinner, sharper, more radiant, more transparent. 4 / Soothing of the skin
But : évaluer l'apaisement de la peau après utilisation du concentré cellulaire, deux fois par jour, pendant 28 jours. Sujets : 18 volontaires. Protocole : Questionnaire d'auto-évaluationPurpose: To evaluate the soothing of the skin after using the cell concentrate, twice a day, for 28 days. Topics: 18 volunteers. Protocol: Self-Assessment Questionnaire
Résultats : comme le montre la figure 7, le concentré cellulaire apaise entre 80 et 90% des sujets.Results: As shown in Figure 7, the cell concentrate soothes between 80 and 90% of subjects.
5/ Optimisation de l'efficacité des soins associés5 / Optimizing the effectiveness of associated care
But : évaluer et comparer, en double aveugle, la cinétique (tO, t2h, t4h, t6h, t8h) d'hydratation du Concentré Cellulaire couplé à la Crème Hydra Ressourçante commercialisée par Institut Esthederm versus la Crème Hydra Ressourçante après une application unique.Aim: to evaluate and compare, in double blind, the kinetics (tO, t2h, t4h, t6h, t8h) of hydration of the Cellular Concentrate coupled with the Hydra Ressourçante Cream marketed by Institut Esthederm versus Hydra Ressourçante Cream after a single application.
Sujets : 10 volontaires (âgés de 23 à 55 ans) ayant la peau sèche ou moyennement hydratée au niveau des avant-bras.Subjects: 10 volunteers (aged 23 to 55 years) with dry or moderately hydrated skin in the forearms.
Protocole : mesures réalisées à l'aide d'un cornéomètre. Résultats : comme le montre la figure 8, le Concentré Cellulaire couplé à la CrèmeProtocol: measurements using a corneometer. Results: as shown in Figure 8, Cellular Concentrate coupled with Cream
Hydra Ressourçante permet d'augmenter le taux d'hydratation cutanée de quasimentHydra Ressourçante makes it possible to increase the cutaneous hydration rate of almost
70% en 2 heures et cette action persiste jusqu'à 8h (+40% seul, +50% couplé). 70% in 2 hours and this action persists until 8h (+ 40% alone, + 50% coupled).

Claims

REVENDICATIONS
1/ Composition cosmétique topique comprenant : un extrait aqueux d'une algue dénommée Blidingia Minima, - un extrait aqueux d'une algue dénommée Laminaria Saccharina, un extrait huileux d'une algue dénommée Laminaria Ochroleuca.1 / Topical cosmetic composition comprising: an aqueous extract of an alga called Blidingia Minima, - an aqueous extract of an alga called Laminaria Saccharina, an oily extract of an alga called Laminaria Ochroleuca.
2/ Composition selon la revendication 1, caractérisée en ce qu'elle contient en outre un extrait aqueux de plancton.2 / Composition according to claim 1, characterized in that it further contains an aqueous extract of plankton.
3/ Composition selon la revendication 2, caractérisée en ce qu'elle contient (en pourcentage en poids) : de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux de Blidingia Minima, - de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux de3 / Composition according to claim 2, characterized in that it contains (in percentage by weight): from 0.2 to 5%, preferably from 0.5 to 2% by weight of an aqueous extract of Blidingia Minima, - from 0.2 to 5%, preferably 0.5 to 2% by weight of an aqueous extract of
Laminaria Saccharina, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait huileux de Laminaria Ochroleuca, de 0.05 à 5%, de préférence de 0.05 à 2% en poids d'un extrait aqueux de plancton.Laminaria Saccharina, from 0.2 to 5%, preferably from 0.5 to 2% by weight of an oily extract of Laminaria Ochroleuca, from 0.05 to 5%, preferably from 0.05 to 2% by weight, of an aqueous plankton extract.
4/ Composition selon l'une des revendications précédentes, caractérisé en ce qu'elle contient au moins un des constituants suivants respectivement : extrait aqueux de soja, - extrait alcoolique de champignon riche en acide agarique, tétrapeptide, éventuellement acétylé, rhamnose.4 / Composition according to one of the preceding claims, characterized in that it contains at least one of the following constituents respectively: aqueous extract of soy, - alcoholic extract of mushroom rich in agaric acid, tetrapeptide, optionally acetylated, rhamnose.
5/ Composition selon l'une des revendications 1 ou 2, caractérisé en ce qu'elle contient en outre : entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% d'un extrait aqueux de soja, entre 0.05 et 2%, avantageusement entre 0.1 et 1% d'un extrait alcoolique de champignon, - entre 1 et 10%, avantageusement entre 2 et 5% d'un tétrapeptide acétylé5 / Composition according to one of claims 1 or 2, characterized in that it further contains: between 0.0005 and 1%, preferably between 0.005 and 0.1% of an aqueous extract of soybean, between 0.05 and 2%, advantageously between 0.1 and 1% of an alcoholic fungus extract, between 1 and 10%, advantageously between 2 and 5% of an acetyl tetrapeptide
(N-Acétyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine) entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% de rhamnose.(N-Acetyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine) between 0.0005 and 1%, advantageously between 0.005 and 0.1% of rhamnose.
6/ Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle se présente sous la forme d'un sérum.6 / Composition according to one of the preceding claims, characterized in that it is in the form of a serum.
11 Composition selon la revendication 1, caractérisée en ce qu'elle contient : de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux deComposition according to Claim 1, characterized in that it contains: from 0.2 to 5%, preferably from 0.5 to 2% by weight, of an aqueous extract of
Blidingia Minima, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait aqueux de Laminaria Saccharina, de 0.2 à 5%, de préférence de 0.5 à 2% en poids d'un extrait huileux deBlidingia Minima, from 0.2 to 5%, preferably from 0.5 to 2% by weight of an aqueous extract of Laminaria Saccharina, from 0.2 to 5%, preferably from 0.5 to 2% by weight of an oily extract of
Laminaria Ochroleuca, de 0.05 à 5%, de préférence de 0.05 à 2% en poids d'un extrait aqueux de plancton. - entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% d'un extrait aqueux de soja, entre 0.05 et 2%, avantageusement entre 0.1 et 1% d'un extrait alcoolique de champignon, avantageusement un extrait de Polyporus Officinalis, entre 1 et 10%, avantageusement entre 2 et 5% de N-Acétyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, entre 0.0005 et 1%, avantageusement entre 0.005 et 0.1% de rhamnose, entre 65 et 85% en poids d'eau, entre 5 et 20% en poids de matière grasse.Laminaria Ochroleuca, from 0.05 to 5%, preferably from 0.05 to 2% by weight of an aqueous plankton extract. between 0.0005 and 1%, advantageously between 0.005 and 0.1% of an aqueous soy extract, between 0.05 and 2%, advantageously between 0.1 and 1% of an alcoholic mushroom extract, advantageously an extract of Polyporus Officinalis, between 1 and and 10%, advantageously between 2 and 5% of N-acetyl L-Glutaminyl L-Aspartyl L-VaIyI L-Histidine, between 0.0005 and 1%, advantageously between 0.005 and 0.1% of rhamnose, between 65 and 85% by weight of water, between 5 and 20% by weight of fat.
8/ Procédé de traitement cosmétique de la peau en vue d'en améliorer l'état et consistant, dans un premier temps, à appliquer la composition objet de l'une des revendication 1 à 7, sur la peau, puis dans un second temps, à appliquer une seconde composition destinée à corriger un dysfonctionnement visible de la peau tel que par exemple déshydratation ou encore hyper séborrhée. 8 / Cosmetic treatment method of the skin to improve its state and consisting, in a first step, to apply the composition object of one of claims 1 to 7, on the skin, then in a second step , to apply a second composition intended to correct a visible dysfunction of the skin such as for example dehydration or hyper seborrhea.
PCT/FR2008/051663 2007-10-02 2008-09-17 Cosmetic composition for improving skin condition WO2009047443A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0758001 2007-10-02
FR0758001A FR2921561B1 (en) 2007-10-02 2007-10-02 COSMETIC COMPOSITION FOR IMPROVING SKIN CONDITION

Publications (2)

Publication Number Publication Date
WO2009047443A2 true WO2009047443A2 (en) 2009-04-16
WO2009047443A3 WO2009047443A3 (en) 2009-06-04

Family

ID=39577549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/051663 WO2009047443A2 (en) 2007-10-02 2008-09-17 Cosmetic composition for improving skin condition

Country Status (2)

Country Link
FR (1) FR2921561B1 (en)
WO (1) WO2009047443A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088225A3 (en) * 2009-01-29 2011-04-28 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin and/or hair care actives
WO2012011905A1 (en) * 2010-07-22 2012-01-26 The Procter & Gamble Company Methods for improving the appearance of hyperpigmented spot(s) with multiple actives
WO2012011904A1 (en) * 2010-07-22 2012-01-26 The Procter & Gamble Company Methods for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina
JP2012519735A (en) * 2010-07-22 2012-08-30 ザ プロクター アンド ギャンブル カンパニー Compositions and methods for inhibiting keratinocyte par2 activation
JP2013035807A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Elastic-fiber formation promotor
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor
JP2014101378A (en) * 2014-02-28 2014-06-05 Procter & Gamble Co Compositions and methods for inhibiting par2 activation of keratinocytes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2980698B1 (en) * 2011-09-29 2015-11-06 Gelyma USE OF A ASSOCIATION OF ALGAE EXTRACTS FOR LIMITING SKIN DISORDERS OF FATTY AND / OR ACNEIC SKIN

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026755A1 (en) * 1996-12-18 1998-06-25 Lancaster Group Gmbh Cosmetic cleansing and skin care preparation containing plant and algae extracts
EP1074262A1 (en) * 1999-08-03 2001-02-07 Societe D'engrais Composes Mineraux Et Amendements (S.E.C.M.A.) Laminaria algae extract, method of preparation and cosmetic or pharmaceutical compositions containing the same
KR20020093364A (en) * 2001-06-08 2002-12-16 애경산업(주) Additive compositions including laminaria saccharina extract for cosmetics and cosmetics containing the same
WO2004004673A1 (en) * 2002-07-08 2004-01-15 Coty B.V. Anti-ageing skin cosmetic
WO2005011716A1 (en) * 2003-07-21 2005-02-10 Henkel Kommanditgesellschaft Auf Aktien Prebiotically active plant extracts
US20060141078A1 (en) * 2004-11-10 2006-06-29 L'oreal Composition comprising a rice protein hydrolysate and an agent for increasing glycosaminoglycan synthesis
EP1759688A1 (en) * 2005-09-05 2007-03-07 L'Oréal Cosmetic method for the care of greasy skin and kit therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026755A1 (en) * 1996-12-18 1998-06-25 Lancaster Group Gmbh Cosmetic cleansing and skin care preparation containing plant and algae extracts
EP1074262A1 (en) * 1999-08-03 2001-02-07 Societe D'engrais Composes Mineraux Et Amendements (S.E.C.M.A.) Laminaria algae extract, method of preparation and cosmetic or pharmaceutical compositions containing the same
KR20020093364A (en) * 2001-06-08 2002-12-16 애경산업(주) Additive compositions including laminaria saccharina extract for cosmetics and cosmetics containing the same
WO2004004673A1 (en) * 2002-07-08 2004-01-15 Coty B.V. Anti-ageing skin cosmetic
WO2005011716A1 (en) * 2003-07-21 2005-02-10 Henkel Kommanditgesellschaft Auf Aktien Prebiotically active plant extracts
US20060141078A1 (en) * 2004-11-10 2006-06-29 L'oreal Composition comprising a rice protein hydrolysate and an agent for increasing glycosaminoglycan synthesis
EP1759688A1 (en) * 2005-09-05 2007-03-07 L'Oréal Cosmetic method for the care of greasy skin and kit therefor

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088225A3 (en) * 2009-01-29 2011-04-28 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin and/or hair care actives
CN102300551A (en) * 2009-01-29 2011-12-28 宝洁公司 Regulation of mammalian keratinous tissue using skin and/or hair care actives
US9676696B2 (en) 2009-01-29 2017-06-13 The Procter & Gamble Company Regulation of mammalian keratinous tissue using skin and/or hair care actives
JP2012520349A (en) * 2010-07-22 2012-09-06 ザ プロクター アンド ギャンブル カンパニー A method for improving the appearance of over-pigmented spots using an extract of ftcomb
JP2012519735A (en) * 2010-07-22 2012-08-30 ザ プロクター アンド ギャンブル カンパニー Compositions and methods for inhibiting keratinocyte par2 activation
JP2012519734A (en) * 2010-07-22 2012-08-30 ザ プロクター アンド ギャンブル カンパニー Method for improving the appearance of a dye-excess spot having a plurality of active substances
WO2012011904A1 (en) * 2010-07-22 2012-01-26 The Procter & Gamble Company Methods for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina
CN103002863A (en) * 2010-07-22 2013-03-27 宝洁公司 Methods for improving the appearance of hyperpigmented spot(s) with multiple actives
CN103002870A (en) * 2010-07-22 2013-03-27 宝洁公司 Methods for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina
CN103002863B (en) * 2010-07-22 2014-11-12 宝洁公司 Methods for improving the appearance of hyperpigmented spot(s) with multiple actives
WO2012011905A1 (en) * 2010-07-22 2012-01-26 The Procter & Gamble Company Methods for improving the appearance of hyperpigmented spot(s) with multiple actives
JP2013035807A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Elastic-fiber formation promotor
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor
JP2014101378A (en) * 2014-02-28 2014-06-05 Procter & Gamble Co Compositions and methods for inhibiting par2 activation of keratinocytes

Also Published As

Publication number Publication date
FR2921561A1 (en) 2009-04-03
FR2921561B1 (en) 2012-11-09
WO2009047443A3 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009047443A2 (en) Cosmetic composition for improving skin condition
EP2662072B1 (en) Active ingredient obtained from Cichorium intybus for action on the skin barrier function similar to that of vitamin D
FR3065172A1 (en) COSMETIC PREPARATION CONTAINING WHITE TRUFFLE EXTRACT AND ASSOCIATED COSMETIC PROCESS
LU93280B1 (en) Cosmetic composition based on extracts of Avena sativa, Lens esculenta and Tropaeolum majus
EP3370833A1 (en) Synergistic extract ofpalmaria palmata
EP2986347B1 (en) Cosmetic applications of lactobacillus pentosus
EP3280497A1 (en) Hydroalcoholic extract ofschinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
EP1830787A1 (en) Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts
FR2896154A1 (en) Cosmetic/dermatological composition, useful for treatment of skin against external aggressions, comprises chestnut leaves extract, chestnut milk, chestnut sugar and an essential oil
EP1165035A2 (en) Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of cd44 membrane receptors of skin cells
EP2763652B1 (en) Use of glucans obtained from prunus persica as an anti-aging cosmetic agent
FR3003167A1 (en) COSMETIC OR DERMATOLOGICAL COMPOSITION AND USE THEREOF
FR3013985A1 (en) MOISTURIZING COMPOSITIONS COMPRISING AT LEAST ONE CAESALPINIA SPINOSA EXTRACT WITH AT LEAST VASELIN AND GLYCERIN
FR3031458B1 (en) SALAD EXTRACTS, COMPOSITIONS AND USES
FR3097767A1 (en) Active ingredient obtained from flowers of Nymphaea alba
FR2799122A1 (en) Vegetable lipid complex, used to hydrate and restructure skin, comprises sphingolipids, glycoceramides, sterols, essential fatty acids, phospholipids and glycolipids
EP3817715B1 (en) Cosmetic use of hrgp (hydroxyproline-rich glycoproteins) from ajuga reptans cells to prevent and/or combat the effects of skin ageing
EP4192417A1 (en) Use of a cosmetic composition for mature skin in the form of a dry and soluble film comprising an extract of tropaeolum majus and an extract of lens esculenta
FR3056106A1 (en) COSMETIC USE OF A COMPOSITION COMPRISING THERMAL WATER IN ASSOCIATION WITH AT LEAST TWO OTHER ACTIVE AGENTS FOR IMPROVING THE GENERAL APPEARANCE OF THE SKIN
WO2007060302A1 (en) Use of a composition containing an ecdysteroid
FR3052666A1 (en) COSMETIC COMPOSITION COMPRISING SOFT ALMOND EXTRACT AND CARE METHOD
FR3052979A1 (en) BIOMIMETIC COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF ARGAN OIL AND HYDROGLYCERIN EXTRACTS OF BROWN ALGAE, ALARIA ESCULENTA AND MYRIT
WO2017153422A1 (en) Fat and/or wax activated by means of the water-insuluble fraction of carica papaya sap
WO2023089288A1 (en) Cosmetic and/or dermatological composition comprising at least one extract of cylindrotheca fusiformis and at least one extract of dunaliella salina, and cosmetic uses thereof
WO2023152080A1 (en) Method for obtaining plant extracts comprising an autofermentation step, compositions comprising such extracts and cosmetic uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08838090

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08838090

Country of ref document: EP

Kind code of ref document: A2